QoLiCOL - Quality of Life in Colon Cancer

Sponsor
Sahlgrenska University Hospital, Sweden (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT02530593
Collaborator
(none)
1,500
1
87
17.2

Study Details

Study Description

Brief Summary

All patients presenting at participating hospitals during the recruitment period with a newly diagnosed colon cancer, regardless of stage and planned treatment, will be eligible for inclusion. They will answer a questionnaire on health related quality of life, physical symptoms, functional impairments and socioeconomic status at diagnosis and after 12, 36 months. Clinical data including recurrence, survival, surgical treatment, oncologic result (pathology report) and adjuvant treatment will be collected from the Swedish ColoRectal Cancer Registry (SCRCR)

Condition or Disease Intervention/Treatment Phase
  • Behavioral: There is no intervention, only observation

Detailed Description

QoLiCOL is an explorative, prospective, longitudinal, non-interventional, international, multicenter study of health-related quality of life, physical symptoms, functional impairments and socioeconomic burden in colon cancer patients. All patients presenting at participating hospitals during the recruitment period with a newly diagnosed rectal cancer, regardless of stage and planned treatment, will be eligible for inclusion. Patients will be followed for 3 years. They will be asked to answer questionnaires at three different time points during follow-up: at diagnosis and after 12 and 36 months. Clinical data, including recurrence, surgical treatment, oncologic result (pathology report) and adjuvant treatment will be collected from the national quality registry for rectal cancer in Denmark and Sweden. As these registries differ in some areas between the countries, additional data will be collected through short CRF:s.

Study Design

Study Type:
Observational
Anticipated Enrollment :
1500 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
QoLiCOL - Quality of Life in Colon Cancer
Study Start Date :
Jun 1, 2015
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Patients with colon cancer

All patients presenting with a newly diagnosed colon cancer regardless of tumour stage

Behavioral: There is no intervention, only observation

Outcome Measures

Primary Outcome Measures

  1. QoL in colon cancer patients [3 years]

    The primary end-point is to describe QoL, symptoms and functional impairments in an unselected population of colon cancer patients

Secondary Outcome Measures

  1. Generate basic descriptive data of the patient population, such as demography, socioeconomic data, disease stage at diagnosis, type of treatment, recurrence and survival [3 years]

  2. Compare differences in QoL between patients with different tumour levels [3 years]

  3. Detect differences in QoL in patients over time after colon cancer treatment [3 years]

  4. Evaluate the effect of complications after colon cancer surgery on the patients socioeconomic situation [3 years]

  5. Evaluate the effect of coping strategies on QoL after initiated treatment [3 years]

  6. Describe patient expectations at diagnosis of colon cancer [3 years]

  7. Identify differences in QoL between patients in different groups regarding gender, age and education level [3 years]

  8. Analyse how clinical factors like oncologic result of operation, morbidity, recurrence and survival influence QoL [3 years]

  9. Identify areas of improvement in treatment and patient care [3 years]

  10. Enable initiation interventional studies when appropriate [3 years]

  11. Analyse health economy aspects of QoL and morbidity in the patient population [3 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Colon cancer newly diagnosed.

  • Planned treatment presented

Exclusion Criteria:
  • No Colon cancer diagnosis,

  • below 18 years of age,

  • no informed consent or withdrawn informed consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sahlgrenska University Hospital/Östra Göteborg Sweden 416 85

Sponsors and Collaborators

  • Sahlgrenska University Hospital, Sweden

Investigators

  • Principal Investigator: Eva Angenete, M.D., Ph.D., SSORG

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Eva Angenete, Principal Investigator, Sahlgrenska University Hospital, Sweden
ClinicalTrials.gov Identifier:
NCT02530593
Other Study ID Numbers:
  • QoLiCOL
First Posted:
Aug 21, 2015
Last Update Posted:
Jul 16, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 16, 2021